Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Prana Thoracic Announces Series A Financing
Prana Thoracic, a medical device company developing the first minimally invasive lung tissue excision tool […]
Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy
Porton Advanced and DanausGT Biotechnology have announced a strategic collaboration in gene and cell therapy […]
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
Sesen Bio, today announced that its stockholders have voted to approve all proposals, including the […]
Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation […]
Sitero Appoints Jeff Huntsman as Chief Commercial Officer
Sitero is pleased to announce the addition of Jeff Huntsman to its growing leadership team […]
Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew […]
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics and Dynacure announced today that the companies have signed a definitive merger agreement to […]
Aptar Appoints Julie Xing to its Board of Directors
Aptar Group, a global leader in drug delivery, consumer product dispensing and active material science […]
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
Poseida Therapeutics, a clinical-stage cell and gene therapy company advancing a new class of treatments […]
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology
Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more